BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 990 filers reported holding BAXTER INTL INC in Q4 2022. The put-call ratio across all filers is 0.54 and the average weighting 0.1%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $856,000 | -81.0% | 15,902 | -77.3% | 0.05% | -76.1% |
Q2 2022 | $4,508,000 | -57.1% | 70,185 | -48.3% | 0.22% | -62.9% |
Q1 2022 | $10,518,000 | +253.2% | 135,648 | +291.0% | 0.59% | +429.7% |
Q4 2021 | $2,978,000 | +135.4% | 34,694 | +120.5% | 0.11% | +70.8% |
Q3 2021 | $1,265,000 | -88.2% | 15,731 | -88.2% | 0.06% | -85.9% |
Q2 2021 | $10,747,000 | +2134.3% | 133,502 | +2240.9% | 0.46% | +1611.1% |
Q1 2021 | $481,000 | -88.8% | 5,703 | -89.3% | 0.03% | -92.4% |
Q4 2020 | $4,290,000 | -22.6% | 53,467 | -22.4% | 0.36% | -40.9% |
Q3 2020 | $5,540,000 | +28.1% | 68,892 | +37.2% | 0.60% | -16.3% |
Q2 2020 | $4,324,000 | +211.5% | 50,223 | +193.8% | 0.72% | +328.0% |
Q1 2020 | $1,388,000 | -55.1% | 17,094 | -53.7% | 0.17% | -33.6% |
Q4 2019 | $3,091,000 | +285.9% | 36,959 | +303.5% | 0.25% | +416.3% |
Q3 2019 | $801,000 | +281.4% | 9,160 | +257.5% | 0.05% | +172.2% |
Q2 2019 | $210,000 | -18.6% | 2,562 | -19.4% | 0.02% | -53.8% |
Q1 2019 | $258,000 | -40.8% | 3,178 | -52.0% | 0.04% | -69.8% |
Q4 2018 | $436,000 | – | 6,622 | – | 0.13% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |